Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2025 results exceeding the market’s revenue expectations, but sales ...

Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 7.1% in the afternoon session after the company trimmed the upper ...

We may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...

A nationwide Danish cohort study demonstrated no increased risk of serious adverse events following vaccination with JN.1-updated mRNA COVID-19 vaccines, reinforcing their safety profile and ...

Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.

Heart attacks remain a leading cause of death and disability worldwide. The permanent loss of heart muscle cells—known as ...

An mRNA cancer vaccine triggered strong immune responses and improved treatment outcomes in mice, offering a new approach to ...

Stock futures edged down Friday morning as investor sentiment took a hit from concerns over the economic impact of higher ...

Researchers found that the stereochemistry of lipids like ALC-315 affects mRNA drug safety and efficacy, offering a path to ...

The experimental mRNA vaccine developed at the University of Florida has shown the ability to supercharge the immune system ...

Researchers at Harvard Medical School and Brigham and Women's Hospital designed an ingestible capsule that delivers liquid ...